Get notified of page updates
Education > XRAY > Search Results

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

How To Use XRAY
Search for Articles Submit an Article for Review
1 through 10 of 110

Relevance: Medium

Research Timeline: Human Research

View Related Clinical Trials

Update : Breast cancer vaccine trial begins enrolling people with BRCA1 and PALB2 mutations

Most relevant for: People at risk of TNBC undergoing prophylactic bilateral mastectomy

A new vaccine was first tested on people diagnosed with triple-negative breast cancer. The vaccine is now being tested to prevent breast cancer among people with an inherited mutation in BRCA1 or PALB2 who are at high risk and who are planning to have a risk-reducing mastectomy. (Posted 1/9/23)

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

Study : Male breast cancer: Patient and surgeon experiences

Most relevant for: Men with breast cancer

By surveying male breast cancer patients and the surgeons who treat them, researchers gained insight into the experiences of both groups, shedding light on an important issue for men with breast cancer. (Posted 12/22/22)

Read More

Relevance: High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Study : Prostate cancer screening may benefit people with Lynch syndrome

Most relevant for: People with Lynch syndrome

Initial results from the IMPACT trial show that PSA testing to screen for prostate cancer in people with Lynch syndrome can detect aggressive early prostate cancers. These findings support the use of PSA screening in men with Lynch syndrome, particularly men with an inherited mutation in an MSH2 or MSH6 gene. (Posted 11/10/22)

Read More

Relevance: Medium-High

Strength of Science: Medium

Research Timeline: Post Approval

View Related Clinical Trials

Study : More is not better: PARP dose can be safely reduced for people with ovarian cancer

Most relevant for: People taking a PARP inhibitor for ovarian cancer maintenance therapy

Maintenance therapy with a PARP inhibitor is now the standard of care for many people with advanced or recurrent ovarian cancer. However, PARP inhibitors may have significant side effects. This study shows that reducing the dose of a PARP inhibitor does not affect survival. (Posted 11/8/22)

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Study : Teens and young adults respond well to learning about familial cancer risk

Most relevant for: Mothers who have had genetic testing for BRCA1 or BRCA2 whether or not they have been diagnosed with breast or ovarian cancer

Little is known about how awareness of hereditary cancer in a high-risk family affects the quality of life of teens and young adults. This study looked at the lifestyle choices, cancer awareness and quality of life of adolescents and young adults whose mothers had undergone testing for a BRCA mutation. (Posted 10/11/2022)

Read More

Relevance: High

Research Timeline: Post Approval

View Related Clinical Trials

Update : PARP inhibitors withdrawn as third-line or later treatment for recurrent ovarian cancer

Most relevant for: people with recurrent ovarian cancer who have received 3 or more prior lines of treatment and who have an inherited or tumor mutation in BRCA1 or BRCA2 or whose tumor is HRD positive

Survival data from a clinical trial signaled that PARP inhibitors may not work as well as chemotherapy for patients with recurrent ovarian cancer who have received three or more lines of treatment. As a result, FDA approvals have been withdrawn for PARP inhibitors in this setting.  This does not affect PARP inhibitor approvals for use as maintenance therapy for ovarian cancer. (Posted 10/4/22)

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Study : PARP inhibitor treatment for metastatic prostate cancer shows most benefit in men with inherited BRCA mutations

Most relevant for: People with metastatic castration resistant prostate cancer who have an inherited or tumor mutation in BRCA2.

This study looked at the benefit of using the PARP inhibitor niraparib to treat metastatic castration-resistant prostate cancer (mCRPC). Participants included those with an inherited or tumor mutation in BRCA1 or BRCA2 or an inherited or tumor mutation in another gene that affects DNA repair. Participants with an inherited or tumor mutation in BRCA1 or BRCA2 had better survival compared to those without a BRCA mutation. Side effects from niraparib were common, and consistent with previous reports for PARP inhibitors.  (posted 9/6/2022)

Read More

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Screening for pancreatic cancer detects early-stage disease and improves survival

Most relevant for: People at increased risk for pancreatic cancer because of family history or an inherited mutation.

A research study has shown that screening for pancreatic cancer in people with an inherited mutation or family history was able to detect early-stage pancreatic cancers and improve survival. These results will likely change pancreatic cancer screening guidelines for high-risk individuals (Posted 8/30/22)

Read More

Relevance: High

Quality of Writing: High

View Related Clinical Trials

Article : Rise in endometrial cancer affects Black women more than white women

Most relevant for: People concerned about their risk for endometrial cancer

The New York Times calls attention to the increase in a type of cancer of the uterus called endometrial cancer and how it disproportionately affects Black women. The article provides useful information about endometrial cancer while raising awareness of a significant and growing health disparity.  (Posted 8/16/22)

Read More

Relevance: High

Quality of Writing: Medium-High

Article : How your ovarian cancer diagnosis can help your relatives

Most relevant for: People diagnosed with ovarian cancer

This media article provides tips from experts and the CDC for talking to family members after a diagnosis of ovarian cancer. It highlights which family members may be at risk of developing ovarian cancer or passing on genes that increase risk. The article provides links to resources, talking points, alternative methods of communication and potential reactions. (Posted 7/28/22)

Read More